One-year all-cause mortality in hospitalized patients with COVID-19 and end-stage renal disease undergoing hemodialysis

医学 终末期肾病 优势比 透析 血液透析 内科学 置信区间 回顾性队列研究 死亡率 2019年冠状病毒病(COVID-19) 疾病 传染病(医学专业)
作者
Jair Munoz Mendoza,Laura Aponte Becerra,Carlos Alberto Torres,Jhoan B. Rozas,Patrick François,Juan D. Salcedo Betancourt,Alfredo Barreto,Juanly Rodriguez,Maritza Suarez,Alessia Fornoni,Gabriel Contreras
出处
期刊:Clinical Nephrology [Dustri-Verlag]
卷期号:99 (2): 51-57 被引量:4
标识
DOI:10.5414/cn110823
摘要

Patients with end-stage renal disease (ESRD) on dialysis and COVID-19 infection have an increased risk of in-hospital mortality, but whether these patients have a higher long-term mortality risk is unknown.Retrospective chart review of 958 patients admitted with COVID-19 infection or those with ESRD admitted for any other reason between February 2020 and August 2020. We collected data on demographics, comorbidities, laboratory tests, and mortality. The primary outcome was all-cause 1-year mortality. The secondary outcome was in-hospital mortality. We used primarily logistic regression models to assess the mortality risk.In total, 651 patients without ESRD with COVID-19 (COVID+ESRD-), 259 with ESRD without COVID-19 (ESRD+COVID-), and 48 with ESRD with COVID-19 (COVID+ESRD+) were hospitalized between February 2020 and August 2020. Patients were followed after discharge until September 2021. The all-cause 1-year mortality rates were 24% in patients with COVID+ESRD-, 22% in ESRD+COVID- patients, and 40% in those with COVID+ESRD+ (p < 0.05). Compared to the COVID+ESRD- group, the unadjusted and adjusted odds ratio (OR) for all-cause 1-year mortality in the COVID+ESRD+ group was 2.13 (95% confidence interval (CI), 1.16 - 3.91) and 2.15 (95% CI,1.12 - 4.14), respectively. The unadjusted and adjusted OR for all-cause in-hospital mortality in the COVID+ESRD+ group was 1.79 (95% CI, 0.92 - 3.49); and 1.79 (95% CI, 0.88 - 3.65), respectively. We found no statistically significant difference between the COVID+ESRD- and ESRD+COVID- groups for both in-hospital and 1-year mortality (p > 0.05).Patients with COVID+ESRD+ have significantly higher odds for all-cause 1-year mortality compared to COVID+ESRD- patients. Future studies should investigate the mechanisms of long-term mortality risk in ESRD patients with COVID-19 infection.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
刚刚
1秒前
Ulrica完成签到,获得积分10
1秒前
1秒前
怕黑笑卉完成签到,获得积分10
2秒前
2秒前
3秒前
Hello应助三木采纳,获得10
3秒前
852应助wang采纳,获得10
4秒前
4秒前
领导范儿应助hu采纳,获得10
5秒前
颠哥完成签到,获得积分10
5秒前
Qing发布了新的文献求助10
5秒前
栀染发布了新的文献求助10
5秒前
XL应助JR采纳,获得10
6秒前
6秒前
cy发布了新的文献求助10
6秒前
z不停发布了新的文献求助10
6秒前
香蕉觅云应助叫兽采纳,获得10
7秒前
7秒前
豌豆颠颠发布了新的文献求助10
7秒前
ding应助只想困瞌睡采纳,获得10
7秒前
7秒前
Aiden发布了新的文献求助10
8秒前
distance完成签到,获得积分10
10秒前
10秒前
11秒前
11秒前
每天发布了新的文献求助10
11秒前
12秒前
临在完成签到,获得积分10
15秒前
15秒前
好运常在完成签到,获得积分10
15秒前
16秒前
17秒前
笨笨的巧凡完成签到,获得积分10
17秒前
英俊的铭应助Aiden采纳,获得10
18秒前
炎炎夏无声完成签到 ,获得积分10
18秒前
过时的疾发布了新的文献求助10
18秒前
高分求助中
Principles of Economics, 11th Edition 10000
University Physics with Modern Physics, 16th edition 10000
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
48V Low-voltage Power Distribution Network (PDN) Architecture Industry Report, 2024 800
ズームレンズの光学設計に関する研究 800
Fundamentals of Pharmaceutical and Biologics Regulations: A Global Perspective, Second Edition 700
Matrix Methods in Data Mining and Pattern Recognition Second Edition 610
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 工程类 有机化学 化学工程 生物化学 计算机科学 内科学 物理 复合材料 催化作用 细胞生物学 无机化学 光电子学 物理化学 电极 基因
热门帖子
关注 科研通微信公众号,转发送积分 7300434
求助须知:如何正确求助?哪些是违规求助? 8918749
关于积分的说明 18888418
捐赠科研通 6965274
什么是DOI,文献DOI怎么找? 3211133
关于科研通互助平台的介绍 2380360
邀请新用户注册赠送积分活动 2187852